

Ref: FOI/GS/ID 7567

Please reply to: FOI Administrator Trust Management Maidstone Hospital Hermitage Lane Maidstone, Kent

Email: mtw-tr.foiadmin@nhs.net

www.mtw.nhs.uk

ME16 9QQ

27 July 2022

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Oesophageal and Gastric cancer.

You asked:

- Q1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:
- a. CAPOX (Capecitabine with Oxaliplatin)
- b. FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)
- c. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- d. Any other systemic anti-cancer therapy
- e. Palliative care only
- Q2. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:
- a. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
- b. Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)
- c. Nivolumab monotherapy
- d. Nivolumab and Ipilimumab
- e. Any other systemic anti-cancer therapy
- f. Palliative care only
- Q3. Please provide the total number of patients treated in the last 3 months with any systemic anti-cancer therapy for:
- a. Oesophageal cancer (any type or stage)
- b. Oesophageal adenocarcinoma (any stage)
- c. Oesophageal squamous cell carcinoma (any stage)
- d. Gastric cancer (any type or stage)
- e. Cancer of the gastro-oesophageal junction (any stage)

Trust response:

- 1.
- a. 1
- b. 2
- c. 0
- d. 14
- e. 4
- 2.
- a. 2
- b. 40
- c. 4
- d. 0
- e. 13
- f. 6
- 3.
- a. 58
- b. 42
- c. 8
- d. 17
- e. 5